Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 07 February 2014 | By Alexander Gaffney, RAC,
Extensive new draft guidance released this week by the US Food and Drug Administration (FDA) makes formal recommendations on how sponsors of analgesic painkillers should develop their products in preparation for eventual marketing authorization.
The 35-page draft guidance, Analgesic Indications: Developing Drug and Biological Products, is intended for sponsors of analgesic products intended to treat acute, chronic and breakthrough pain.
All three types of pain-acute, chronic and breakthrough-are characterized by the need for long-term, regular treatment with analgesics. FDA notes that while it is important to understand how a single dose of the drug works, it's even more interested in understanding how the drug functions as part of a long-term regimen.
The guidance contains a plethora of advice for companies seeking ultimate approval.
"Specifically, this guidance focuses on drug development and trial design issues and chemistry, manufacturing, and controls concerns that are unique to the study of acute, chronic, and breakthrough pain and the labeling considerations for analgesic drugs," FDA explained in the preamble of the guidance.
One early consideration noted by FDA is the type of pain indication being sought by a sponsor. Regulators recommended that sponsors meet with FDA prior to the initiation of a Phase 3 clinical study to discuss proposed indications and whether or not they are feasible to obtain.
From there, FDA recommends four general approaches based on a novelty scale ranging from the newest drugs (i.e. New Molecular Entities), to reformulated drugs, add-on indications and additional claims.
Those approaches are then broken down by the type of pain experienced by patients, with FDA recommending specific approaches for each.
The guidance also speaks to various stages of clinical development, including the considerations each stage of a clinical trial should take into account with respect to safety, endpoints, patient populations, trial designs, routes of drug administration and more.
Comments on the guidance should be submitted to FDA by 7 April 2014.
Analgesic Indications: Developing Drug and Biological Products
Federal Register
Tags: Painkiller
Regulatory Focus newsletters
All the biggest regulatory news and happenings.